A case of a lichenoid eruption secondary to a PD-1 inhibitor

Immune checkpoint inhibition is an increasingly common therapy for various cancers including melanoma and nonsmall cell lung cancer. Inhibition of the cytotoxic T lymphocyte antigen-4 (CTLA-4) or the programmed death receptor-1 (PD-1)/ PD ligand-1 (PD-L1) signaling pathways enhance T cell activation and promotes cytotoxic activity against cancer cells. However, the nonspecific response promoted by these inhibitors have led to a variety of adverse dermatologic effects. We review the case of a progressive lichenoid eruption in a patient on nivolumab and review cutaneous toxicities from this class of medications.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research